title: Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study.
abstract: In order to determine the clinical impact of CD34+ cell selected autologous transplantation in multiple myeloma (MM), we have performed a retrospective case-controlled analysis comparing 21 MM patients receiving high-dose melphalan and autologous transplantation with CD34+ peripheral blood stem cells (PBSC) as front-line therapy to 21 control patients receiving unselected products. Case matching was performed using the following criteria: age and beta2-microglobulin at diagnosis and disease status at the time of transplantation. Both cohorts were homogeneous in term of induction treatment and conditioning regimen. Patients were collected for CD34+ selection after priming with G-CSF alone. Significantly fewer CD34+ cells/kg were infused to patients in the selected group as compared to patients in the control group: 2.2 (range 0.5-14.3) vs 9.4 (range 1.1-15) (P < 0.001). The median time to neutrophil recovery > or =0.05 x 10(9)/l was 10 days for the CD34+ group and 9.5 days for the control group (P = 0.357). The median time to platelet recovery > or = 20 x 10(9)/l was 9 days for the CD34+ group and 4.5 days for the control group (P = 0.005). Response rates were comparable in both groups (85.7% in the CD34+ group vs 90.4% in the control group). At 3 years, event-free survival (32% in the CD34+ group vs 39% in the control group) and overall survival (85% in the CD34+ group vs 79% in the control group) were not significantly different. Finally, use of unselected products dramatically reduced the cost of the transplantation procedure. This study shows that CD34+ cell selected autologous transplantation is more expensive than transplantation with unselected products and does not improve the clinical outcome of patients with MM.
authors.affiliation: Department of Hematology, CHU Hôtel-Dieu, Nantes, France.
authors.forename: N
authors.initials: N
authors.lastname: Morineau
authors.forename: X W
authors.initials: XW
authors.lastname: Tang
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: B
authors.initials: B
authors.lastname: Mahé
authors.forename: R
authors.initials: R
authors.lastname: Bataille
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D018952:Antigens, CD34 / Q000276:immunology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002469:Cell Separation; D003365:Costs and Cost Analysis; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D016019:Survival Analysis; D019172:Transplantation Conditioning; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018952:Antigens, CD34; D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone